Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29428949 | 1.00 | NOTUM (0.65) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL30954331 | 0.81 | NOTUM (0.59) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL2692515 | 0.81 | NOTUM (0.59) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL24110388 | 0.80 | NOTUM (0.57) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL24109961 | 0.80 | NOTUM (0.57) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL28394067 | 0.79 | TSHR (0.57) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL29506395 | 0.79 | NOTUM (1.00) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL41252 | 0.79 | NOTUM (1.00) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL1151123 | 0.78 | NOTUM (0.70) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL10477477 | 0.78 | NOTUM (0.70) | NOTUMTSHRRAB9AL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117956991-A | N, N-dimethyltryptamine and related hallucinogens and uses thereof | 人类生物科学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-113912529-B | Method for synthesizing indole compounds by catalyzing N-aryl amide compounds and vinylene carbonate with ruthenium | 成都大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-113979995-A | MEK inhibitor and application thereof in medicine | 贝达药业股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113912529-A | Method for synthesizing indole compound by catalyzing N-aryl amide compound and vinylene carbonate with ruthenium | 成都大学 | 2022-01-11 | — | — | CN | disclosed |
| US-8168833-B2 | Schwartz reagents: methods of in situ generation and use | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2012-05-01 | — | — | US | disclosed |
| US-20100145060-A1 | Schwartz Reagents: Methods of In Situ Generation and Use | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
| EP-2094692-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008057856-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| CN-1906169-A | Therapeutic agents I | ASTRAZENECA AB (SE) | 2007-01-31 | — | — | CN | disclosed |
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036114-A1 | COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3 | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | disclosed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001095903-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | disclosed |
| EP-0734386-A1 | PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES | Abbott Laboratories (US) | 1996-10-02 | — | — | EP | disclosed |
| WO-1995016687-A1 | PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES | ABBOTT LABORATORIES (US) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145060-A1 | Schwartz Reagents: Methods of In Situ Generation and Use | CBR3, CBR1, ZFR | NOTUM 537/4885TSHR 1090/4885RAB9A 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.